Claudin 6 expression is useful to distinguish myxofibrosarcomas from other myxoid soft tissue tumors

Hirofumi Bekki, Hidetaka Yamamoto, Katsumi Takizawa, Takeshi Iwasaki, Hiroshi Otsuka, Yuichi Yamada, Kenichi Kouhashi, Katsumi Harimaya, Yukihide Iwamoto, Yoshinao Oda

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Myxofibrosarcoma (MFS) is characterized by abundant myxoid stroma, a wide spectrum of cytological atypia, and frequent local recurrence. Some soft tissue tumors with myxoid stroma can histologically mimic MFS, but have different biological behaviors. Here we sought to identify a useful diagnostic marker for MFS. After our analysis of the gene expression dataset from the Gene Expression Omnibus database, we focused on claudin 6 (CLDN 6). The status of CLDN 6 was assessed by immunohistochemistry in 61 samples of MFS and other (benign) myxoid soft tissue tumors (28 myxoma samples, 12 nodular fasciitis samples), 18 low-grade fibromyxoid sarcoma, 30 myxoid liposarcoma, 29 extraskeletal myxoid chondrosarcoma and 27 dedifferentiated liposarcoma with myxoid feature samples. The correlation between the expression of CLDN 6 and clinicopathological findings in MFS was also investigated. Immunohistochemically, high expression of CLDN 6 was observed in approx. 65% of the MFSs, whereas the benign soft tissue tumors did not show a high expression of CLDN 6. The expression of CLDN 6 in the MFS was significantly higher than those of other tumor specimens. Among the MFSs, the high expression of CLDN 6 was correlated with high FNCLCC grades and high AJCC stages. CLDN 6 may be useful for the differential diagnosis from benign myxoid tumor and for predicting the aggressive biological behavior of MFS.

元の言語英語
ページ(範囲)674-679
ページ数6
ジャーナルPathology Research and Practice
213
発行部数6
DOI
出版物ステータス出版済み - 6 1 2017

Fingerprint

Neoplasms
Myxoid Liposarcoma
Fasciitis
Gene Expression
Liposarcoma
Myxoma
claudin 6
Sarcoma
Differential Diagnosis
Immunohistochemistry
Databases
Recurrence

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Cell Biology

これを引用

Claudin 6 expression is useful to distinguish myxofibrosarcomas from other myxoid soft tissue tumors. / Bekki, Hirofumi; Yamamoto, Hidetaka; Takizawa, Katsumi; Iwasaki, Takeshi; Otsuka, Hiroshi; Yamada, Yuichi; Kouhashi, Kenichi; Harimaya, Katsumi; Iwamoto, Yukihide; Oda, Yoshinao.

:: Pathology Research and Practice, 巻 213, 番号 6, 01.06.2017, p. 674-679.

研究成果: ジャーナルへの寄稿記事

@article{a2761fef69d045939bd04ab939ff90bf,
title = "Claudin 6 expression is useful to distinguish myxofibrosarcomas from other myxoid soft tissue tumors",
abstract = "Myxofibrosarcoma (MFS) is characterized by abundant myxoid stroma, a wide spectrum of cytological atypia, and frequent local recurrence. Some soft tissue tumors with myxoid stroma can histologically mimic MFS, but have different biological behaviors. Here we sought to identify a useful diagnostic marker for MFS. After our analysis of the gene expression dataset from the Gene Expression Omnibus database, we focused on claudin 6 (CLDN 6). The status of CLDN 6 was assessed by immunohistochemistry in 61 samples of MFS and other (benign) myxoid soft tissue tumors (28 myxoma samples, 12 nodular fasciitis samples), 18 low-grade fibromyxoid sarcoma, 30 myxoid liposarcoma, 29 extraskeletal myxoid chondrosarcoma and 27 dedifferentiated liposarcoma with myxoid feature samples. The correlation between the expression of CLDN 6 and clinicopathological findings in MFS was also investigated. Immunohistochemically, high expression of CLDN 6 was observed in approx. 65{\%} of the MFSs, whereas the benign soft tissue tumors did not show a high expression of CLDN 6. The expression of CLDN 6 in the MFS was significantly higher than those of other tumor specimens. Among the MFSs, the high expression of CLDN 6 was correlated with high FNCLCC grades and high AJCC stages. CLDN 6 may be useful for the differential diagnosis from benign myxoid tumor and for predicting the aggressive biological behavior of MFS.",
author = "Hirofumi Bekki and Hidetaka Yamamoto and Katsumi Takizawa and Takeshi Iwasaki and Hiroshi Otsuka and Yuichi Yamada and Kenichi Kouhashi and Katsumi Harimaya and Yukihide Iwamoto and Yoshinao Oda",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.prp.2016.12.001",
language = "English",
volume = "213",
pages = "674--679",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "6",

}

TY - JOUR

T1 - Claudin 6 expression is useful to distinguish myxofibrosarcomas from other myxoid soft tissue tumors

AU - Bekki, Hirofumi

AU - Yamamoto, Hidetaka

AU - Takizawa, Katsumi

AU - Iwasaki, Takeshi

AU - Otsuka, Hiroshi

AU - Yamada, Yuichi

AU - Kouhashi, Kenichi

AU - Harimaya, Katsumi

AU - Iwamoto, Yukihide

AU - Oda, Yoshinao

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Myxofibrosarcoma (MFS) is characterized by abundant myxoid stroma, a wide spectrum of cytological atypia, and frequent local recurrence. Some soft tissue tumors with myxoid stroma can histologically mimic MFS, but have different biological behaviors. Here we sought to identify a useful diagnostic marker for MFS. After our analysis of the gene expression dataset from the Gene Expression Omnibus database, we focused on claudin 6 (CLDN 6). The status of CLDN 6 was assessed by immunohistochemistry in 61 samples of MFS and other (benign) myxoid soft tissue tumors (28 myxoma samples, 12 nodular fasciitis samples), 18 low-grade fibromyxoid sarcoma, 30 myxoid liposarcoma, 29 extraskeletal myxoid chondrosarcoma and 27 dedifferentiated liposarcoma with myxoid feature samples. The correlation between the expression of CLDN 6 and clinicopathological findings in MFS was also investigated. Immunohistochemically, high expression of CLDN 6 was observed in approx. 65% of the MFSs, whereas the benign soft tissue tumors did not show a high expression of CLDN 6. The expression of CLDN 6 in the MFS was significantly higher than those of other tumor specimens. Among the MFSs, the high expression of CLDN 6 was correlated with high FNCLCC grades and high AJCC stages. CLDN 6 may be useful for the differential diagnosis from benign myxoid tumor and for predicting the aggressive biological behavior of MFS.

AB - Myxofibrosarcoma (MFS) is characterized by abundant myxoid stroma, a wide spectrum of cytological atypia, and frequent local recurrence. Some soft tissue tumors with myxoid stroma can histologically mimic MFS, but have different biological behaviors. Here we sought to identify a useful diagnostic marker for MFS. After our analysis of the gene expression dataset from the Gene Expression Omnibus database, we focused on claudin 6 (CLDN 6). The status of CLDN 6 was assessed by immunohistochemistry in 61 samples of MFS and other (benign) myxoid soft tissue tumors (28 myxoma samples, 12 nodular fasciitis samples), 18 low-grade fibromyxoid sarcoma, 30 myxoid liposarcoma, 29 extraskeletal myxoid chondrosarcoma and 27 dedifferentiated liposarcoma with myxoid feature samples. The correlation between the expression of CLDN 6 and clinicopathological findings in MFS was also investigated. Immunohistochemically, high expression of CLDN 6 was observed in approx. 65% of the MFSs, whereas the benign soft tissue tumors did not show a high expression of CLDN 6. The expression of CLDN 6 in the MFS was significantly higher than those of other tumor specimens. Among the MFSs, the high expression of CLDN 6 was correlated with high FNCLCC grades and high AJCC stages. CLDN 6 may be useful for the differential diagnosis from benign myxoid tumor and for predicting the aggressive biological behavior of MFS.

UR - http://www.scopus.com/inward/record.url?scp=85018991378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018991378&partnerID=8YFLogxK

U2 - 10.1016/j.prp.2016.12.001

DO - 10.1016/j.prp.2016.12.001

M3 - Article

VL - 213

SP - 674

EP - 679

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 6

ER -